Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -246.51M | -212.83M | -166.57M | -140.72M | -137.08M |
| Total Depreciation and Amortization | 9.80M | 5.20M | 4.99M | 4.87M | 4.79M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.58M | 32.25M | 6.73M | 19.09M | 23.38M |
| Change in Net Operating Assets | -19.70M | 32.08M | 33.69M | -49.52M | -2.49M |
| Cash from Operations | -224.83M | -143.31M | -121.17M | -166.27M | -111.40M |
| Capital Expenditure | -8.42M | -12.05M | -9.76M | -26.75M | -30.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 123.55M | 133.22M | 87.50M | 150.07M | -527.14M |
| Cash from Investing | 115.13M | 121.17M | 77.74M | 123.32M | -557.17M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.42M | 306.00K | 3.24M | 6.05M | 5.99M |
| Repurchase of Common Stock | -1.01M | -3.98M | -6.01M | -- | -1.09M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 5.29M | -5.29M | -- |
| Cash from Financing | 2.41M | -3.67M | 2.52M | 759.00K | 4.91M |
| Foreign Exchange rate Adjustments | 176.00K | 291.00K | 800.00K | 1.17M | 1.35M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.12M | -25.52M | -40.11M | -41.03M | -662.31M |